CSF1R and familial pancreatic carcinoma: A dose-escalation phase I study is currently underway to evaluate the safety and activity of an anti-PDL1 antibody (Durvalumab) in combination with a small-molecule CSF-1R tyrosine kinase inhibitor (Pexidartinib) in patients with metastatic/advanced pancreatic cancer or CRC [49].